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Impaired metabolism of high density lipoprotein in uremic patients. We
measured lipoproteins, apolipoproteins, lipoprotein lipase (LPL), he-
patic triglyceride lipase (HTGL), lecithin: cholesterol acyltransferase
(LCAT) and parameters of calcium metabolism to evaluate the roles of
these enzymes and hypertriglyceridemia for impaired high-density
lipoprotein (HDL) metabolism in chronic renal failure, and to examine
the impact of altered calcium homeostasis on the lipoprotein-regulating
enzymes. The subjects were 25 healthy volunteers and 66 uremic
patients, 24 treated with hemodialysis (HD) and 42 with continuous
ambulatory peritoneal dialysis (CAPD). Lipoprotein analysis revealed:
(I) reduction in HDL cholesterol especially in HDL2 subfraction; (2)
increase in HDL triglyceride; and (3) decreased ratio of HDL2 choles-
terol to HDL3 cholesterol in both HD and CAPD patients. Simple
regression analysis showed: (I) a positive correlation between VLDL
triglyceride and triglyceride/cholesterol ratio of HDL; (2) positive
correlations of LPL level in post-heparin plasma to cholesterol concen-
trations in HDL2, HDL3 and total HDL, and to apolipoproteins A-I and
A-Il; and (3) inverse correlations of HTGL to HDL2 cholesterol and to
the ratio of HDL2 cholesteroLlHDL3 cholesterol. Multiple regression
analysis of MDL cholesterol indicated positive association with LPL
and inverse correlation with VLDL triglyceride. Four variables includ-
ing LPL, HTGL, LCAT and VLDL triglyceride explained 51.5% of the
variation of HDL cholesterol. HDL2 cholesterol was associated posi-
tively with LPL and negatively with VLDL triglyceride in the model.
HDL3 cholesterol was associated positively with LPL, HTGL and
LCAT and inversely with VLDL triglyceride. Stepwise multiple regres-
sion analysis indicated that independent predictors of HTGL were
gender, parathyroid hormone levels by a mid-portion assay, ionized
calcium and age, and that those of LCAT were ionized calcium and age.
These results suggest that elevated VLDL and alterations in the enzyme
levels contributed to deranged MDL metabolism in uremic patients, and
that changes in the enzyme levels were associated with impaired
calcium homeostasis.
Patients with chronic renal failure are at an increased risk for
atherosclerosis [1], and metabolic abnormalities associated with
uremia may stimulate the atherogenesis. Impaired lipoprotein
metabolism is often observed in uremic patients [2—41 and one
of the major abnormalities is decreased high density lipoprotein
(HDL) cholesterol [5, 61. Although low HDL cholesterol is an
independent risk factor for atherosclerosis [7, 81, the mecha-
nism of HDL abnormality in uremia is not fully understood.
Plasma lipoproteins are metabolized and regulated by several
enzymes including lipoprotein lipase (LPL), hepatic triglyceride
lipase (HTGL), and lecithin:cholesterol acyltransferase (LCAT).
Previous studies revealed that uremic patients have reduced
[9—121 or normal [13, 141 activity of LPL and remarkably low
HTGL activity [9—14] in post-heparin plasma. LPL and HTGL
have potential effects on HDL metabolism as shown in non-
uremic subjects [15—17]. LPL generates precursor of HDL
during lipolysis of triglyceride-rich lipoproteins, and HTGL
promotes the conversion of HDL2 to HDL3. Uremic patients on
hemodialysis have low activity of LCAT which esterifies cho-
lesterol and incorporates cholesteryl ester into HDL core [18,
191. Furthermore, inverse correlation between serum triglycer-
ide and HDL cholesterol levels suggests the interaction of HDL
with triglyceride-rich lipoproteins [201. Thus it is possible that
hypertriglyceridemia and alterations of these three enzymes
affect HDL metabolism in chronic renal failure, and it is
important to determine the mechanisms of changes in these
enzymes in uremia. Deranged calcium regulation is another
metabolic consequence of uremia. Uremic patients have im-
paired activation of vitamin D by the kidney, hypocalcemia,
hyperphosphatemia, and secondary hyperparathyroidism [21,
221. Since calcium has diverse effects on biological functions,
altered calcium homeostasis may result in other metabolic
disturbances. Recent studies by us [23, Note added in proof]
and others [24, 251 have shown the relationship between cal-
cium and lipoprotein metabolism experimentally. Akmal et al
[261 have shown in uremic dogs that excess parathyroid hor-
mone suppressed post-heparin lipolytic activity. These experi-
mental data raise the hypothesis that impaired calcium regula-
tion affects HDL metabolism in uremic patients by altering the
levels of the enzymes which are involved in lipoprotein metab-
olism. The purpose of this study is to evaluate the roles of the
enzymes and hypertriglyceridemia for derangement of HDL
metabolism in uremic patients, and to examine the possible
effects of deranged calcium metabolism on alterations in ii-
poprotein-regulating enzymes in uremic patients.
Methods
Subjects
The 93 Japanese subjects consisted of 25 healthy volunteers,
24 uremic patients treated on HD and 44 patients on CAPD.
Diabetic subjects were excluded. Mean ages (± SE) of each
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group were 49.2 2.9, 50.8 1.8 and 50.5 1.7 years,
respectively, and these are not statistically different. Genders
(male/female) were 14/11, 12/12 and 24/18, respectively, and
were not different statistically. Body mass indices (23.5 0.6,
23.2 0.8, 21.9 0.4 kglm2, respectively) were also compara-
ble among the three groups. RD patients received 12 to 15 hours
of HD every week using bicarbonate dialysate containing 3.5
mEq/liter calcium (Kindaly AF-1P, Fuso, Japan). CAPD pa-
tients used three or two bags of 1 to 1.5 liter intraperitoneal
dialysate containing 1.5% glucose (Dianeal 1.5, Baxter, Round
Lake, Illinois, USA) and one or two bags of 1 to 1.5 liter
dialysate containing 2.5% glucose (Dianeal 2.5, Baxter) every
day. la-hydroxyvitamin D3 was administered to 17 RD patients
(average 0.47 jig/day) and 40 CAPD patients (average 0.42
jig/day). Four HD and one CAPD patients received 0.25 jig/day
of 1 ,25-dihydroxyvitamin D3. Calcium carbonate was pre-
scribed for 10 HD (average 2.6 glday) and 20 CAPD patients
(average 2.6 g/day). Also, four RD and two CAPD patients took
aluminum hydroxide gel (average 1.6 and 2.3 g/day, respective-
ly). No patient received lipid lowering drugs.
Blood sampling
All blood samples were obtained after a more than 12 hour
fast. Fresh blood collected in a heparinized syringe was used for
ionized calcium measurement. Serum was obtained by centrif-
ugation at 1500 g for 20 minutes at room temperature and used
for the measurement of lipoproteins, apolipoproteins, parathy-
roid hormone, total calcium and phosphorus. Plasma for LCAT
activity was prepared from blood collected in a tube containing
sodium EDTA which was immediately cooled in iced water
after sampling. For LPL and HTGL measurements, blood was
collected 10 minutes after intravenous injection of sodium
heparin (30 U/kg body wt) in a tube containing sodium EDTA
and was immediately cooled in iced water. Post-heparin plasma
was obtained by centrifugation at 1,500 g for 10 minutes at 4°C
and was stored below —40°C until LPL and HTGL assays were
performed.
Analysis of lipoproreins and apolipoproteins
Serum lipoproteins were analyzed by one-step preparative
ultracentrafugation described by Bronzert and Brewer [271 with
modification, Lipoproteins were fractioned into five classes
according to density: very low density lipoprotein (VLDL, d <
1.006), intermediate density lipoprotein (IDL, d 1.006 to
1.019), low density lipoprotein (LDL, d = 1.019 to 1.063), high
density lipoprotein-2 (HDL2, d = 1.063 to 1.125), and high
density lipoprotein-3 (HDL3, d> 1.125). Serum of each donor
was transferred in four tubes (0.20 ml per tube, 0.5PC tube,
Hitachi), and added with the same volume of KBr solution to
adjust solvent density to 1.006, 1.019, and 1.063 and 1.125 g/ml,
respectively. They were spun at 100,000 rpm (436,000 x g) for
three hours at 4°C in a Hitachi RP100 AT2 rotor. Cholesterol
and triglyceride concentrations were measured by enzymatical
methods (Cholesterol HR, Wako, Osaka; Clinimate TG-2,
Daiichi, Tokyo) in whole serum, the d < 1.006 fraction
(VLDL), the d < 1.019 fraction (VLDL + IDL), the d < 1.063
fraction (VLDL + IDL + LDL), the d> 1.063 fraction (HDL2
+ HDL), and the d> 1.125 fraction (HDL3). Lipid content in
each lipoprotein fraction was calculated by subtraction.
Serum concentrations of apolipoprotein (apo) A-I and A-TI
were measured by immunoturbidimetry (ApoAuto II, Daiichi,
Japan).
Enzyme assay
Plasma LCAT activity was measured by the method de-
scribed by Nagasaki and Akanuma [28]. For LPL and HTGL,
we measured both lipolytic activities and immunoreactive pro-
tein masses in post-heparin plasma. LPL and HTGL activities
were measured using [3H]-triolein emulsified with gum arabic as
described elsewhere [4]. Immunoreactive LPL and HTGL
masses were measured by sandwich-enzyme immunoassay
(EIA) systems developed by Ikeda et al [29] using monoclonal
antibodies to each enzyme.
Parathyroid hormone and other measurements
Parathyroid hormone (PTH) was measured by two assay
methods. One was radioimmunoassay using antibodies recog-
nizing the mid- and C-terminal portion of the peptide hormone
(PTH-HS, Yamasa Shoyu, Japan) [30]. The other was a two-site
immunoradiometric assay using two different antibodies spe-
cific to N- and C-terminus, respectively, of the hormone mole-
cule (Allegro Intact PTH, Nichols Institute Diagnostics, Cali-
fornia, USA) [311. Plasma ionized calcium was measured by a
calcium-selective ion electrode method (Horiba, Japan). Total
calcium and phosphorus concentrations were measured by
routine laboratory methods.
Statistics
Difference among means was evaluated by one way analysis
of variance (ANOVA) with multiple comparison (Scheffe
F-test). Correlational studies were done by either simple linear
regression or multiple regression analysis. P values less than
0.05 were taken as significant. In stepwise multiple regression
analysis, F-to-enter value was set at 4.0.
Results
Lipoproteins and apolipoproteins
In RD patients, serum cholesterol concentration was not
different from the normal value. However, its distribution in
lipoprotein fractions was altered (Table 1). Cholesterol levels in
IDL were significantly increased, whereas LDL cholesterol was
not elevated. VLDL cholesterol increased with marginal signif-
icance (P 0.056). HDL cholesterol was significantly lower in
HD patients than in healthy subjects. Although cholesterol
levels in both HDL2 and HDL3 subfractions were decreased in
HD patients, the reduction was more evident in HDL2 subfrac-
tion. The ratio of HDL2 cholesterol to HDL3 cholesterol was
significantly lower in HD patients than in healthy subjects. In
CAPD patients, serum cholesterol level was significantly in-
creased when compared with either that in healthy subjects or
that in RD patients. Changes in cholesterol distribution among
lipoprotein fractions were similar to that in RD patients, and
CAPD patients had increased levels of VLDL and IDL choles-
terol and decreased HDL cholesterol. IDL cholesterol in CAPD
patients was four times as high as the normal value. Changes in
cholesterol concentration in HDL subfractions were similar to
those in HD patients. Both HD and CAPD patients showed a
significant elevation in serum triglyceride concentration. They
had significantly increased triglyceride levels in VLDL, IDL
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Table 1. Analysis of Iipoproteins and apolipoproteins
Significance
Control HD CAPD by ANOVA
Cholesterol mg/dl
Serum 187.6 8.4 185.5 9.3 223.4 8.7" 0.0045
VLDL 23.0 1.5 43.9 7.2 54.8 4.6" 0.0002
IDL 5.3 ii 13.6 j•4 22.4 l.5Ic 0.0001
LDL 103.6 6.9 93.4 8.8 109.4 7.4 NS
HDL 55.6 2.6 34.6 2.8a 36.9 17b
HDL2
HDL3
37.8 2.3
17.8 0.5
21.8 2.4a
12.8 0.6k
21.6 14b
15.3 0.6""
0.0001
0.0001
Triglyceride mg/dl
Serum 68.2 7.9 188.9 32.7a 209.6 0.0001
VLDL 30.2 4.5 121.6 3Q•Q 124.2 16.2" 0.0026
LDL 5.7 0.8 13.6 1.4 18.9 l.4l,c 0.0001
LDL 19.6 2.8 36.1 3.4' 47.6 3.2" 0.0001
HDL 12.7 0.9 16.1 1.6 18.9 0.8" 0.0003
Apolipoproteins mg/dl
apo A-I 121.7 4.4 106.9 5.1 116.6 4.0 NS
apo A-Il 28.9 1.1 25.8 1.0 25.7 1.0 NS
Ratios
HDL2-C/HDL3-C mg/mg
HDL-TG/HDL-C mg/mg
HDL-C/(A-I + A-Il) mol/mol
2.13 0.12
0.237 0.020
23.0 1.2
1.68 0.15
0.531 0.073
17.4 0.8a
1.44 0.10"
0.551 0.033"
17.3 0.61
0.0008
0.0001
0.0002
HDL-TG/(A-I + A-Il) moi/moi 2.38 0.21 3.81 Ø47a 3.93 0.16" 0.0041
Difference among the three groups were evaluated by one way analysis of variance (ANOVA).
Abbreviations are: apo, apolipoprotein; HDL-C, HDL cholesterol; HDL2-C, HDL2 cholesterol; HDL3-C, HDL3 cholesterol; HDL-TG, HDL
triglyceride. Data are mean SE.
Significant difference (P < 0.05) assessed by multiple comparison (Scheffe F-test) between control and HDa, between control and CAPDb, and
between HD and CAPD".
and LDL. Increase in HDL triglyceride was significant in
CAPD patients.
There was no significant difference in either apo A-I or A-I!
among the three groups. Triglyceride/cholesterol ratio in HDL
fraction was significantly higher in both HD and CAPD patients
than in the control subjects, indicating the alteration of HDL
lipid composition in the uremic patients. Compositional change
of HDL was also significant when assessed by molar ratios of
HDL cholesterol/(apo A-I + apo A-Il) and HDL triglyceride!
(apo A-I + apo A-I!). These results indicate cholesterol deple-
tion and triglyceride enrichment of HDL in the uremic patients.
LPL, HTGL and LCAT
We first examined the relationship between immunoreactive
LPL mass and LPL activity as shown in Figure 1, because a
previous study suggested the presence of inhibitor(s) of LPL
activity in uremic plasma [32] whereas others could not confirm
it [9, 13]. We found a linear relationship between immunoreac-
tive LPL mass and LPL activity either in the healthy subjects,
HD or CAPD patients. There was no significant difference in
the slope of the fitting lines among the three groups. This was
also the case with HTGL. These results indicate that changes in
post-heparin LPL and HTGL activities in uremic patients are
due to changes in enzyme protein concentrations. Therefore,
we employed the values of immunoreactive protein concentra-
tions for LPL and HTGL in the study below.
Table 2 summarizes the results of comparison among groups
and between genders in the levels of LPL, HTGL and LCAT.
LPL level in HD patients tended to be lower than that in the
healthy subjects, although the difference was not significant.
CAPD patients had a mean LPL which was not different from
the normal value. There was no significant difference in LPL
protein concentration between genders. HTGL protein levels
were significantly lower in both HD and CAPD patients than
those of the healthy subjects. Significant difference was ob-
served in HTGL protein levels between male and female in each
of the three groups. Men had 1.7 to 2.5 times higher HTGL
protein mass than women. LCAT activity in HD patients was
significantly lower than the control value, whereas CAPD
patients had almost normal LCAT activity. No consistent
difference was seen in LCAT activities between genders.
Calcium, phosphorus and PTH
There was no significant difference in serum total calcium
concentrations among the three subject groups. However, HD
and CAPD patients had significantly lower ionized calcium
levels than healthy group, as shown in Table 3. Both uremic
groups also showed hyperphosphatemia. They had extremely
high immunoreactive PTH levels measured by either the mid-
portion assay or the sandwich assay.
Simple regression analysis of HDL metabolism
By simple regression analysis in the total subjects, LPL
correlated positively to HDL cholesterol and apo A-I (Fig. 2).
LPL also correlated significantly to HDL2 cholesterol (r =
0.392, P = 0.001), HDL3 cholesterol (r = 0.320, P = 0.01) and
apo A-Il (r = 0.331, P = 0.005). HTGL correlated inversely to
HDL2 cholesterol and to the ratio of HDL2 cholesterollHDL3
cholesterol in uremic patients (Fig. 3). In these relations, the
correlation coefficients became improved when analyzing the
subjects with HTGL less than 700 ng!ml (r = —0.563, P =
0.0002 and r = —0.559, P = 0.0002, respectively), suggesting
HTGL deficiency becomes more critical in that range. There
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Fig. 1. Correlation between enzyme protein concentration and lipo-
lytic activity in LPL and HTGL. Open circle (0), closed circle (S) and
closed square (U) indicate healthy subjects, HD and CAPD patients,
respectively.
was no significant correlation between HTGL and HDL3 cho-
lesterol, apo A-I or apo A-TI. There was no demonstrable
correlation of LCAT activity to any parameter of HDL metab-
olism when assessed by simple regression analysis. There was
an inverse correlation between HDL cholesterol and serum
triglyceride (r —0.588, P = 0.0001). The inverse correlation
remained significant when analyzed in each of the three groups
separately. An inverse correlation was also found between
HDL cholesterol and VLDL triglyceride (r —0.560, P =
0.0001). HDL triglyceride correlated positively to VLDL tri-
glyceride (r = 0.490, P = 0.0001). We found a significant
positive correlation between VLDL triglyceride and the triglyc-
eride/cholesterol ratio in HDL fraction (r = 0.777, P 0,0001).
Multiple regression analysis of factors affecting HDL
metabolism
Based on the above results, data were analyzed by multiple
regression method. In this model, HDL-, HDL2- or HDL3-
cholesterol was an dependent variable and independent varia-
Table 2. Comparison of LPL, HTGL and LCAT levels b
genders and among groups
etween
Control HD CAPD ANOVA
LPL
Male 175.6 10.0 148.8 18.7 159.3 13.7 NS
Female 173.8 13.5 141.4 15.8 202.1 21.1 NS
Total 174.8 8,0 145.1 12.0 177.0 12.2 NS
HTGL
Male 1565 175 792 154' 865 86" 0.0003
Female 870 142 322 70' 515 55b 0.0007
Total 1259 134 557 96 720 61" 0.0001
LCAT
Male 80.9 8.3 41.4 8.1k 69.5 5.lc 0.0057
Female 62.2 16.1 52.3 8.0 85.3 5.8c 0.0112
Total 74.0 5.4 47.1 5,7a 76.0 4,QC 0.0002
Difference among the three groups were evaluated by one way400 analysis of variance (ANOVA).
Difference in HTGL between genders was significant (P < 0.05) in
each group. There was no significant gender difference either in LPL or
in LCAT in each group. Data are mean SE.
Significant difference (P < 0.05) assessed by multiple comparison
(Scheffe F-test) between control and HDa, between control and CAPDb,
and between HD and CAPDC,
Table 3. Calcium and related parameters in the subjects
Control HD CAPD ANOVA
Ca mEq/liter 4.56 0.03 4.62 0.10 4.61 0.06 NS
Phosphorus 3.26 0.09 6.17 0.36a 6.37 0.20" 0.0001
mg/dlCa mmol/ 1.17 0.01 0.97 0.03' 1.07 002 0.0001
liter
m-PTH 243 31 21067 4559' 20100 3584" 0.006
34 3 267 sia 253 33b 0.0001
Difference among the three groups were evaluated by one way
analysis of variance (ANOVA).
In the comparison of m- and intact PTH, log-transformed values gave
similar statistical results. Data are mean SE.
Significant difference (P < 0.05) assessed by multiple comparison
(Scheffe F-test) between control and HDa, between control and CAPDb,
and between HD and CAPDC.
bles consisted of LPL, HTGL, LCAT and VLDL triglyceride
(Table 4). VLDL triglyceride was log-transformed to fit the
linear model. There were independent associations of HDL
cholesterol with LPL and VLDL triglyceride levels. HDL2
cholesterol also had independent relationships with LPL and
VLDL triglyceride. HDL3 cholesterol showed significant rela-
tionship with LPL, HTGL, LCAT and VLDL triglyceride.
HDL triglyceride was significantly related with LPL and VLDL
triglyceride. HDL triglyceride also showed inverse association
with HTGL with borderline significance (P = 0.0524). In the
model, the four independent variables explained 51.5%, 46.9%,
38.6% and 34.6% of the variations of HDL-, HDL2-, and
HDL3-cholesterol and HDL triglyceride levels, respectively.
Relationship between calcium metabolism and lipoprotein-
regulating enzymes
Possible correlations were examined between parameters of
calcium metabolism and the lipoprotein-regulating enzyme lev-
els by simple regression analysis. For HTGL, male and female
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Fig. 2. Correlation between LPL and HDL parameters. Open circle
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Fig. 3. Correlation between HTGL and HDL metabolism. Closed
circle (•) and closed square () indicate HD and CAPD patients,
respectively. HDLC2, HDL2-C cholesterol: HDLC-C, HDL3
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Table 4. Multiple regression analysis of factors affecting HDL lipids
in total subjects
Variables
Dependent Independent 13 value R2
HDL-C
Abbreviations are: 13, standard regression coefficient; R2, multiple
coefficient of determination; HDL-C, HDL cholesterol; HDL2-C,
HDL2 cholesterol; HDL3-C, HDL3 cholesterol; HDL-TG, HDL triglyc-
eride; VLDL-TG, VLDL triglyceride.
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subjects were analyzed separately because HTGL levels were
significantly different between genders. LPL showed no signif-
icant correlation with total calcium, phosphorus, ionized cal-
cium, mid-portion PTH or intact PTH level. HTGL and LCAT
also showed no correlation to total calcium, phosphorus, mid-
portion PTH or intact PTH level. However, we found a
significant positive correlation between ionized calcium and
HTGL level (r = 0.344, P = 0.0143 for male; r = 0.318, P =
0.0486 for female). There was also a positive correlation be-
tween ionized calcium and LCAT activity (r 0.249, P
0.0365).
Furthermore, we examined the independent factors affecting
the three enzymes using stepwise multiple regression analysis
among the variables including age, gender, total and ionized
calcium, phosphorus, log-transformed m- and intact PTH levels
(Table 5). No variable was entered as a significant predictor of
LPL. Gender, log(m-PTH), ionized calcium and age were
indicated as independent predictors of HTGL. Ionized calcium
and age were entered as independent predictors of LCAT.
Discussion
The purpose of this study was to evaluate the roles of LPL,
HTGL, LCAT and hypertriglyceridemia for deranged HDL
metabolism in uremic patients, and to examine the possible
0.29 1
0.124
0.068
—0.597
0.284
0.084
—0.004
—0.573
0.204
0.206
0.271
—0.445
0.323
—0.200
0.037
0.524
0.0018
NS
NS
0.0001
0.0035
NS
NS
0.0001
0.0467
0.0399
0.0083
0.0001
0.0028
0.0524
NS
0.0001
0.515 (P = 0.0001)
0.469 (P = 0.0001)
0.386 (P = 0.0001)
0.346 (P = 0.0001)
impact of altered calcium metabolism on these lipoprotein-
regulating enzymes. The HD and CAPD patients had decreased
HDL cholesterol levels, altered HDL subfraction distribution,
and compositional changes in HDL fraction. Univariate and
multivariate regression analyses indicated the contributions of
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Table 5. Stepwise multiple regression analysis of factors affecting
HTGL and LCAT
Step Variable entered /3 F value R2
HTGL I
2
3
4
Gender
log (m-PTH)Ca
Age
—0.483
—0.22
0.231
—0.198
27.4
5.5
6.1
4.6 0.370
LCAT I
2
Ca
Age
0.256
—0.237
4.9
4.2 0.116
Significant predictors of HTGL and LCAT were explored among the
parameters including gender, age, total calcium, Ca phosphorus, log
(m-PTH) and log (intact PTH) by stepwise multiple regression analysis.
Dummy variables were used for genders (male = 1, female = 2). F value
to enter was set at 4.0 at each step. Final results were given in the
Table. /3, standard regression coefficient; R2, multiple coefficient of
determination.
LPL, HTGL, LCAT and VLDL triglyceride levels to HDL
metabolism. The multiple regression model including the three
enzymes and log-transformed VLDL triglyceride value as inde-
pendent variables explained 51.5% of the variation of HDL
cholesterol in the study subjects. Stepwise multiple regression
analyses revealed significant positive association of ionized
calcium to HTGL and LCAT and inverse relation between PTH
and HTGL. These results suggest that HDL abnormality in
uremia is largely attributable to alterations in the enzymes and
VLDL level, and that suppression of HTGL and LCAT is
associated with impaired calcium metabolism.
It is well known that low HDL cholesterol is often associated
with hypertriglyceridemia [20]. We confirmed the inverse cor-
relation between HDL cholesterol and triglyceride levels in
serum and VLDL. There is a hypothesis that increased triglyc-
eride and decreased HDL are the results of lowered LPL
activity [33] based on the fact that HDL precursor "nascent
HDL" is generated from surface remnant of triglyceride-rich
lipoproteins during hydrolysis of core triglyceride by LPL [34,
35]. We confirmed significant positive correlations of LPL to
HDL cholesterol, HDL2 cholesterol, HDL3 cholesterol and
apolipoproteins A-I and A-Il. Also, multiple regression analysis
indicated that LPL was an independent factor affecting HDL
metabolism. These data are compatible with the view that a
considerable amount of HDL is derived from LPL action.
However, mean LPL level was not significantly decreased in
either HD or CAPD patients who had marked reduction in HDL
cholesterol. In previous studies, low HDL cholesterol was
repeatedly found although LPL was not always decreased in
uremia [13, 14]. Thus, although LPL is one of the important
factors determining HDL cholesterol level, it seems difficult to
explain low HDL cholesterol levels in uremia by changes in
LPL level only.
In the HD and CAPD patients, HDL cholesterol was de-
creased whereas HDL triglyceride was increased, indicating
compositional change of HDL lipids. VLDL triglyceride corre-
lated positively to HDL triglyceride and inversely to HDL
cholesterol. Triglyceride/cholesterol ratio of HDL fraction was
increased in the uremic patients, and the ratio correlated
positively to VLDL triglyceride concentrations, indicating that
accumulation of VLDL was associated with triglyceride enrich-
ment and cholesterol depletion of HDL. This reciprocal rela-
tionship between HDL triglyceride and HDL cholesterol in the
presence of hypertriglyceridemia was probably due to enhanced
lipid transfer reaction. Lipid transfer reaction between HDL
and less dense lipoproteins, especially VLDL, is mediated by
cholesteryl ester transfer protein (CETP) [36]. CETP mediates
transfer of triglycerides from VLDL to HDL, and cholesteryl
ester transfer in the opposite direction, resulting in enrichment
of HDL with triglyceride and depletion of HDL cholesterol.
Elevated level of VLDL, in other words, hypertriglyceridemia,
stimulates this process [37]. Thus it is probable that hypertri-
glyceridemia led to compositional change of HDL lipids and
subsequent reduction in HDL-cholesterol. Since HDL2 is a
main donor of cholesteryl ester, cholesterol reduction was more
evident in HDL2 than HDL5 subfraction in the patients. Also,
enhanced lipid transfer may account for the accumulation of
cholesterol-rich remnant lipoprotein in uremia.
A recent study in non-uremic subjects by Brinton, Eisenberg
and Bre slow [38] has shown that compositional change of HDL
expressed by the decreased ratio of HDL cholesterol/(apo A-I
+ apo A-TI) was associated with increased fractional catabolic
rate of HDL apolipoproteins and reduced HDL cholesterol
level. They speculated that low ratio of HDL cholesteroll(apo
A-I + apo A-I!) was due to enhanced lipid transfer. The uremic
patients in the present study had a significantly decreased ratio
of HDL cholesterol/(apo A-I + apo A-Il) and increased ratio of
HDL triglyceride/(apo A-I + apo A-TI). These data were in line
with the above report by Brinton et al, and raised the possibility
that enhanced lipid transfer could reduce HDL cholesterol not
only by changing composition of HDL but also by stimulating
the catabolism of HDL. Clearly, in vivo kinetic study in uremic
patients is needed to evaluate the latter possibility.
Normally, enrichment of HDL2 with triglyceride is followed
by depletion of the lipid by HTGL, converting HDL2 to HDL3
[35, 391. In univariate analysis in HD and CAPD patients,
HTGL inversely correlated to HDL2 cholesterol and to the ratio
of HDL2 cholesterol/HDL3 cholesterol. By multivariate regres-
sion analysis in the total subjects, HTGL correlated positively
to HDL3 cholesterol and inversely to HDL triglyceride with
borderline significance, although the relationship between
HTGL and HDL2 cholesterol became insignificant. These re-
sults are in agreement with a previous study in the general
population [171 and suggest that decreased FITGL in uremia
was associated with impaired conversion of HDL2 to HDL3.
This relationship between HTGL and HDL subfractions may
predict that the lowered HTGL is followed by increased HDL2
cholesterol levels, whereas HDL2 cholesterol was decreased in
the patients. This apparent discrepancy may be explained by
the result of multiple regression analysis indicating that YLDL
triglyceride was the most powerful predictor of HDL2 choles-
terol. The positive effect of low HTGL on HDL2 cholesterol
was overcome by the negative effect of high VLDL.
LCAT is the key enzyme which keeps the chemical gradient
of cholesterol from cells to plasma [40]. At the surface of HDL,
LCAT catalyzes the esterification of free cholesterol and incor-
porates cholesteryl ester into HDL core. By LCAT action HDL
particles become "mature" from nascent HDL with discoidal
shape to spherical HDL3 and finally HDL2 [35j. Previous
studies showed decreased LCAT activity in HD patients [18,
19], and one may speculate that decreased HDL2 cholesterol is
related to low LCAT activity. In the present study, both HD
and CAPD patients had low HDL2 cholesterol, whereas LCAT
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Fig. 4. Proposed alterations in HDL
metabolism in uremic patients. HDL
precursor is derived from secretion by the
liver and intestine and from hydrolysis of
triglyceride-rich lipoproteins by LPL. The
precursor undergoes conversion to HDL3 and
finally HDL2 by the action of LCAT. CETP
mediates the exchange of cholesteryl ester of
HDL2 for triglyceride of triglyceride-rich
lipoproteins, resulting in triglyceride-
enrichment and cholesterol-depletion of HDL.
HDL triglyceride can be removed by HTGL
and this promotes re-conversion of HDL2 to
HDL3. In uremia, patients with reduced LPL
have decreased HDL formation and
subsequent reduction in HDL3-, HDL2- and
total HDL-cholesterol. Decreased LCAT
(especially in HD patients) is followed by the
lowered HDL3 formation. Elevated VLDL
triglyceride promotes the CETP-mediated lipid
transfer and HDL becomes triglyceride-
enriched and cholesterol-depleted.
Remarkable decrease in HTGL accounts for
impaired re-conversion of HDL2 to HDL3.
Decreased LCAT is associated with low
ionized calcium. Decreased HTGL is also
associated with low plasma ionized calcium
and elevated parathyroid hormone levels, both
of which are the consequences of uremia.
was decreased only in HD patients. The latter finding is similar
to the result by Dieplinger, Schoenfeld and Fielding [41].
Multivariate regression analysis did not indicate significant
association of LCAT and HDL2 cholesterol level. The enzyme,
however, showed a significant positive relationship with HDL3
cholesterol. These data suggest that LCAT plays an important
role in the formation of HDL3, but its influence on HDL2
metabolism becomes less when compared with the larger effects
of VLDL and LPL.
In this work, 51.5% of variation in HDL cholesterol was
explained by VLDL triglyceride, LPL, HTGL and LCAT. The
remaining portion was unexplained by the four variables. This
part would be comprised of variations in secretion of HDL
precursor by the liver and intestine, HDL receptor activity,
apolipoprotein loss into peritoneal dialysate in CAPD patients
[42] and CETP activity. CETP activity is reported to be reduced
in uremia [41, 43]. A recent work in nephrotic syndrome has
shown the increased CETP mass and negative correlation
between CETP and HDL [441. The effect of CETP on plasma
concentration and composition of HDL has been characterized
in patients heterozygous and homozygous for CETP deficiency
[45]. Thus, the inclusion of CETP assay in our study could
improve the result by multiple regression analyses.
It is not known at present why the levels of the lipoprotein-
regulating enzymes are affected in uremia. LPL activity in
post-heparin plasma was reported to be reduced [9—12] or
normal [13, 14]. A previous study suggested the inhibitor of
LPL in uremic plasma [32], whereas others could not confirm it
[9, 13]. We measured LPL by both activity assay and EIA,
because possible discrepancy between the two assay methods
was expected if an inhibitory substance interfered with the
activity assay system. However, we could not find the discrep-
ancy. The result indicates that changes in LPL activity mea-
sured by the method we used were attributable to the changes
in LPL protein concentrations in post-heparin plasma. We,
however, did not rule out impaired in vivo action of LPL due to
altered susceptibility of substrate lipoproteins to the enzyme. It
is possible that decreased ratio of apo C-lI/C-Ill [46] is related
to impaired catabolism of triglyceride-rich lipoprotein in ure-
mia.
Akmal et al recently demonstrated in uremic dogs that excess
PTH caused hypertriglyceridemia by suppressing LPL activity
in post.heparin plasma [26]. However, the relationship between
LPL and PTH was not confirmed in this patient study. Despite
marked reduction of LPL in uremic dogs [26], reported post-
heparin LPL activities are not always low in uremic patients [4,
13, 14]. Change in LPL in uremic patients was not significant
also in the present study, while they had an extremely high level
in circulating PTH. Thus, the effect of PTH on LPL seems to be
less in humans than in the dog. Alternatively, the effect of PTH
was hidden by some factors having greater influence on LPL,
such as insulin resistance or hyperinsulinemia [47], which were
variable among patients.
Decrease in HTGL activity is a consistent finding in uremia
[9—14], although the cause is not clear. Association of decreased
HTGL with reduced glomerular filtration ratio was reported in
chronic renal failure patients without dialysis therapy [48].
Since HTGL is a hepatic enzyme, impaired renal function itself
does not account for the suppression of the enzyme. It is likely
that some metabolic alteration due to renal failure affects liver
function. Using multivariate analysis, we examined possible
relationship between low HTGL and impaired calcium metab-
olism. The result indicated that HTGL level was independently
associated with ionized calcium and PTH concentrations, and
also with age and gender. The age- and gender-related alter-
ations in HTGL are in line with previous reports [46, 501. We
also found a significant relationship between ionized calcium
and LCAT. These data support the hypothesis that impaired
UREMIA
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homeostasis of calcium results in lipoprotein abnormalities
through impairment of the enzymes.
In conclusion, HDL metabolism in uremia is affected by
LPL, HTGL, LCAT and VLDL levels in different ways.
Impaired calcium metabolism seems to be partly responsible for
the alterations in the enzyme. Proposed alterations in HDL
metabolism in uremia are presented in Figure 4. Since de-
creased HDL cholesterol is an independent risk for atheroscle-
rosis, normalization of HDL metabolism may improve the
prognosis of the patients. It appears important to reduce VLDL
triglyceride and to restore the enzymes for amelioration of HDL
metabolism; also improvement of calcium homeostasis may
give a favorable effect on lipoprotein metabolism.
Reprint requests to Yoshiki Nishizawa, M.D., Second Department of
Internal Medicine, Osaka City University Medical School, 1-5-7, Asahi-
machi, Abeno-ku, Osaka 545, Japan.
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